A Phase I/II Randomized Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Trial Profile

A Phase I/II Randomized Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Cancer vaccine (Primary) ; Cancer vaccine (Primary) ; Rintatolimod (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Jul 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.
    • 10 Jun 2017 Biomarkers information updated
    • 21 Jun 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top